Pharmaceutical composition comprising salbutamol

The problems of insufficient atomization performance and stability of existing pharmaceutical compositions are solved through compositions of albutamol, 1,1-difluoroethane, polyethylene glycol and ethanol, and better therapeutic effects and environmentally friendly drug delivery solutions are provided.

CN120379656APending Publication Date: 2025-07-25APTAR FRANCE SAS
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202380052351.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-07-13
Filing Date
2023-07-11
Publication Date
2025-07-25

AI Technical Summary

Technical Problem

Existing pharmaceutical compositions containing albuterol have shortcomings in atomization properties and stability over time, especially the effects of hydrofluoroalkane propellant gas on greenhouse effects and the use of surfactants.

Method used

Compositions of albutamol, 1,1-difluoroethane, polyethylene glycol and ethanol are used as pharmaceutical compositions to optimize the atomization performance and maintain long-term stability. By adjusting the proportion and composition of each component, the use of high global warming potential and surfactants in traditional compositions is avoided.

Benefits of technology

It achieves better atomization performance and long-term stable therapeutic effects, reduces greenhouse gas emissions, and is suitable for the treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0005231252390000011
    Figure HDA0005231252390000011
  • Figure HDA0005231252390000012
    Figure HDA0005231252390000012
  • Figure HDA0005231252390000021
    Figure HDA0005231252390000021
Patent Text Reader

Abstract

The present invention relates to a pharmaceutical composition consisting of the following compounds: a salbutamol-based active ingredient (a), 1, 1-difluoroethane (b), polyethylene glycol (c) and ethanol (d). The invention also relates to the use of such a pharmaceutical composition in the treatment of respiratory diseases, to a canister containing such a pharmaceutical composition and to a metered dose inhaler provided with such a canister. Finally, the invention relates to the use of the pharmaceutical composition and the canister in a metered dose inhaler.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Compositions comprising salbutamol sulphate

    WO2013054135A1

  • Compositions comprising salbutamol sulphate

    WO2013054137A1

  • Composition comprising salbutamol sulphate

    WO2014170689A1